OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502) and its wholly-owned subsidiary, Millennium Pharmaceuticals, Inc., announced today that Millennium has initiated two Phase II clinical trials of MLN8237. The first trial will examine the molecule in adult patients with aggressive non-Hodgkin’s lymphoma (NHL) while the second trial will evaluate the drug in patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). MLN8237 is an oral, selective Aurora A kinase inhibitor discovered and developed by Millennium scientists.
